Resumo

ARIZA, Juan Guillermo  e  MARTINEZ, Jairo Andrés. Farmacoeconomía e Investigación de Resultados en el Síndrome de Intestino Irritable: Revisión de la evidencia con Tegaserod. Rev. gastroenterol. Perú [online]. 2006, vol.26, n.1, pp.77-79. ISSN 1022-5129.

Irritable Bowel Syndrome (IBS) is a chronic and episodic disease that affects 14.5% of females in the United States, and its impact decreases the quality of life. On the other hand, IBS consumes a great part of the health budget and develops indirect costs by loss of work productivity. Currently, Tegaserod, an agonist of the number 4 serotonin receptors (5-HT4), indicated for IBS-Constipation treatment, has demonstrated savings while optimizing health resources and improving the quality of life of patients and their work productivity.

Palavras-chave : Pharmacoeconomics; outcomes research; work productivity; Tegaserod.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )